fingolimod hydrochloride has been researched along with Hepatitis C in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anwar-Hashim, Z; Aslanyan, A; Mihalova, T; Siripurapu, R | 1 |
| Ando, K; Hashimoto, R; Kato, H; Ogawa, T; Otsuka, M; Tagawa, A; Tanabe, H; Tetsuka, S | 1 |
2 other study(ies) available for fingolimod hydrochloride and Hepatitis C
| Article | Year |
|---|---|
Hepatitis C during disease modifying therapy with Fingolimod for Relapsing Remitting Multiple Sclerosis: diagnosis and treatment.
Topics: Female; Fingolimod Hydrochloride; Hepatitis C; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2021 |
Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis.
Topics: Adult; Brain; Cervical Cord; Female; Fingolimod Hydrochloride; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Recurrence | 2016 |